[Effectiveness and safety of biological therapy in patients with severe asthma in a real clinical practice].

Aim: To assess effectiveness and safety of biological therapy in patients with severe asthma during 5 yr follow-up.

Materials And Methods: We recruited 129 adult outpatients (29% males) aged 18-81 yrs with severe asthma were followed up during 5 yrs and were examined for every 3-6 months. Eighty five patients were treated by conventional therapy (ICS/LABA ± tiotropium, montelukast, OCS) only and 44 pts additionally received biologicals (оmalizumab - 9 pts, мepolizumab - 8 pts, benralizumab - 11 pts, dupilumab - 16 pts).

Markers of eosinophilic airway inflammation in patients with asthma and allergic rhinitis.

Measurement of airway inflammation is an important step to determine phenotype of asthma and allergic rhinitis (AR). To assess the level of nitric oxide in exhaled air (FeNO), nasal fraction of nitric oxide (nasal NO), their relationship with clinical control and blood eosinophils in patients with steroid-naive mild and moderate asthma and AR. One hundred forty-seven patients (65 men), ages 26-49.

ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally.

[Development of surgery of the heart and great vessels in Rassia during the first half of the 20th century].

Analysed in the article are scientific priorities of Russian cardiovascular surgeons in the first half of the 20th century, showing rapid and successful development of surgery of the lungs, heart, and great vessels over a comparatively short time period, also underlining the fundamental works of Yu.Yu. Dzhanelidze, S.

Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol.

Randomised controlled trials (RCTs) on the management of COPD exacerbations evaluate heterogeneous outcomes, often omitting those that are clinically important and patient relevant. This limits their usability and comparability. A core outcome set (COS) is a consensus-based minimum set of clinically important outcomes that should be evaluated in all RCTs in specific areas of health care.